Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

Bullboard Posts

Post by Riverfolkon Mar 04, 2020 11:16am

67 Views

Post# 30765397

A growing drug library and now multiple phase 2 possibilitie

A successful Phase I trial is expected to be followed by a Phase II trial to investigate Metablok's efficacy at preventing inflammation in a vital organ. Arch is considering targeting inflammation related acute kidney injury in patients undergoing cardiac surgery as a first Phase II indication and/or a separate trial to target inflammation in the lungs caused by infection.

Bullboard Posts

Crypto and blockchain stock ends year with a profit